Cormorant Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Cormorant Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-200,000	Closed	-$11.9M	–	56
2017 Q3	$11.9M	Hold	200,000	–	–	2.11%	16
2017 Q2	$15.8M	Hold	200,000	–	–	2.62%	15
2017 Q1	$16.6M	Sell	200,000 -210,000	-51%	-$15.6M	2.41%	14
2016 Q4	$32.5M	Sell	410,000 -45,995	-10%	-$3.34M	4.38%	5
2016 Q3	$31.9M	Sell	455,995 -50,000	-10%	-$2.77M	3.52%	7
2016 Q2	$19.6M	Buy	505,995 +5,995	+1%	+$250K	2.78%	9
2016 Q1	$20.3M	Buy	500,000 +100,000	+25%	+$6.34M	3.05%	9
2015 Q4	$35.5M	Buy	400,000 +100,000	+33%	+$7.9M	4.24%	4
2015 Q3	$22.2M	Hold	300,000	–	–	3.55%	7
2015 Q2	$24.3M	Sell	300,000 -416,500	-58%	-$27.1M	3.23%	8
2015 Q1	$30M	Buy	716,500 +316,500	+79%	+$8.98M	4.64%	4
2014 Q4	$6.2M	Hold	400,000	–	–	0.96%	32
2014 Q3	$5.06M	Hold	400,000	–	–	1.04%	29
2014 Q2	$5.73M	Hold	400,000	–	–	1.52%	25
2014 Q1	$5.1M	Buy	+400,000	New	+$5.43M	1.17%	31

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cormorant Asset Management's EGRX Position: Q4 2017 in Review

Cormorant Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2017, closing a stake of 200,000 shares — an estimated $11.9M sold.

Cormorant Asset Management first reported a position in EGRX in Q1 2014 and held it in 15 quarters. The position peaked at $35.5M in Q4 2015. 170 funds tracked by Wall St. Rank hold EGRX as of Q4 2017.

Cormorant Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Cormorant Asset Management sold 200,000 Eagle Pharmaceuticals, Inc. shares in Q4 2017, an estimated $11.9M.
Cormorant Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 15 quarters.
Cormorant Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $35.5M in Q4 2015.
170 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2017.

Based on Cormorant Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.